NASDAQ · Biotechnology

Pharvaris N.V. (PHVS) Stock

$31.69 +1.83% NASDAQ: PHVS Healthcare

Valuation

MetricValue
Price$31.69
Market Cap$2.21B
P/E Ratio-10.26
P/B Ratio6.27
P/S Ratio0.00
EPS (TTM)$-2.97
52-Week High$43.25
52-Week Low$20.65
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-61.24%
ROA-52.20%
ROCE-60.76%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio9.97

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-54.0M$-87.0M$-97.0M$-146.0M$-170.0M
Net Profit$-43.0M$-76.0M$-101.0M$-134.0M$-176.0M
EPS$-1.41$-2.27$-2.63$-2.48$-2.97
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$212.0M$168.0M$399.0M$291.0M$301.0M
Total Liabilities$7.0M$18.0M$15.0M$24.0M$30.0M
Cash$209.0M$162.0M$391.0M$281.0M$292.0M
Borrowings$0$0$0$1.0M$1.0M

Latest News

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy Zacks · Jul 15, 2026 IBM downgraded, Cava upgraded: Wall Street's top analyst calls The Fly · Jul 15, 2026 Wells Fargo Initiates Coverage on Pharvaris With Overweight Rating, $55 Price Target MT Newswires · Jul 15, 2026 Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade Zacks · Jul 14, 2026 Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development Investor's Business Daily · Jul 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-45.0M$-67.0M$-93.0M$-120.0M$-137.0M
Investing Cash Flow$0$0$0$-1.0M$0
Financing Cash Flow$-13.0M$-1.0M$-17.0M$1.0M$-11.0M
Net Cash Flow$111.0M$-48.0M$229.0M$-111.0M$11.0M
Free Cash Flow$-45.0M$-67.0M$-93.0M$-121.0M$-137.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.80
EV / EBITDA-9.40
FCF Yield-8.06%
Quick Ratio11.94
Interest Coverage-2084.33
Return 1Y48.62%
Return 3Y107.86%
Return 5Y136.97%

Ownership

Insiders Held6.14%
Institutions Held85.31%
Institutions Float Held90.89%
Institutional HolderSharesReport Date
General Atlantic, L.P.8,031,2522026-03-31
FMR, LLC6,284,4722026-03-31
Foresite Capital Management IV, LLC4,778,5812026-03-31
venBio Partners LLC4,639,3042026-03-31
Viking Global Investors, L.P.3,653,3102026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCRXBioCryst Pharmaceuticals, Inc. $8.57 +3.44% -5.84 $2.18B 0.00%
BMRNBioMarin Pharmaceutical Inc. $54.90 +0.02% 151.42 $10.61B 0.00%
PHARPharming Group N.V. $9.68 -1.22% 66.30 $685.13M 0.00%
RLYBRallybio Corporation $17.20 +1.24% 2.15 $91.28M 0.00%
TVTXTravere Therapeutics, Inc. $52.40 +0.69% -133.31 $4.87B 0.00%

About Pharvaris N.V.

Pharvaris N.V. (PHVS) stock trades at $31.69 with a market capitalization of $2.21B. The stock is valued at a price-to-earnings (P/E) ratio of -10.26, price-to-book of 6.27, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $20.65 and $43.25, and currently trades 26.7% below its 52-week high.

On profitability, Pharvaris N.V. generates a return on equity (ROE) of -61.24%, return on capital employed of -60.76%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1173.15 +0.30% JNJ Johnson & Johnson $260.24 +1.47% ABBV AbbVie Inc. $276.46 +1.48% MRK Merck & Company, Inc. Common Stock (new) $146.28 +2.74% UNH UnitedHealth Group Incorporated Common Stock (DE) $381.63 +2.88% NVS Novartis AG $143.79 +0.47% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $657.30 +0.82% AMGN Amgen Inc. $416.42 +2.20% GILD Gilead Sciences, Inc. $150.73 +2.47% ABT Abbott Laboratories $99.51 +1.04% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides